BRIUMVI
PeakmAbublituximab
BLAINTRAVENOUSINJECTABLE
Approved
Dec 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
BRIUMVI (ublituximab) is cd20-directed antibody interactions [moa]. First approved in 2022.
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BRIUMVI (ublituximab) is a CD20-directed cytolytic monoclonal antibody approved in December 2022 for relapsing multiple sclerosis and various B-cell malignancies including chronic lymphocytic leukemia, lymphomas, and Waldenström macroglobulinemia. It works by targeting CD20 on B cells, triggering antibody-dependent cellular cytotoxicity and direct cell death. The drug is administered intravenously and represents a distinct mechanism within the crowded CD20-targeted immunotherapy space.
$2.0MPart D
PeakEarly commercial trajectory with modest Part D spending; product is at peak lifecycle stage suggesting stable team investment and execution focus.
Mechanism of Action
CD20-directed Antibody Interactions
Pharmacologic Class:
CD20-directed Cytolytic Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis
Started Jun 2026
240 enrolled
Relapsing Multiple Sclerosis
Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis
Started May 2026
30 enrolled
Multiple Sclerosis (MS) - Relapsing-remitting
A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)
Started Mar 2026
350 enrolled
Multiple Sclerosis
Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
Started Feb 2026
30 enrolled
Autoimmune Disorders
Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis
Started Feb 2026
50 enrolled
Multiple Sclerosis
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.